Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?

Sandralee Blosser, S. L. Maxwell, M. K. Reeves-Hoche, A. R. Localio, C. W. Zwillich

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Study objective: To evaluate the impact of a week-long course of inhaled albuterol compared with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients with stable COPD. Design and interventions: A double-blind, two-period, crossover evaluation, wherein the subjects inhaled albuterol, two puffs four times a day (qid) for 7 days, or ipratropium, two puffs qid for 7 days, in random sequence. Setting: Outpatients of the Pennsylvania State University Hospital, Lebanon VA Medical Center, and local private office practices. Participants: A sample of 15 subjects with stable COPD with FEV1 <55% predicted. Measurements and results: Variables measured at baseline (no inhaled bronchodilator) and/or on day 7 of each arm included FEV1 (liters), 12-min walk test distance (meters), 'rescue' puffs of metaproterenol needed each week, and dyspnea scoring after walking, on the Borg Category Scale (0 to 10=maximal). There was no significant difference in distance walked in 12 min (mean of 751.0±55.5 [±SE]) vs 755.7±61.3 m) or perceived dyspnea (mean 2.7±0.4 vs 3.3±0.4) during albuterol or ipratropium use. Seven patients preferred ipratropium, seven preferred albuterol, and one had no preference. Conclusion: We conclude that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspnea in patients with stable COPD.

Original languageEnglish (US)
Pages (from-to)730-735
Number of pages6
JournalChest
Volume108
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Cholinergic Antagonists
Ipratropium
Dyspnea
Chronic Obstructive Pulmonary Disease
Albuterol
Exercise
Metaproterenol
Lebanon
State Hospitals
Private Practice
Bronchodilator Agents
Walking
Outpatients
Ipratropium Drug Combination Albuterol

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Blosser, Sandralee ; Maxwell, S. L. ; Reeves-Hoche, M. K. ; Localio, A. R. ; Zwillich, C. W. / Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?. In: Chest. 1995 ; Vol. 108, No. 3. pp. 730-735.
@article{f98f2248f4b84214b760631c09f123d1,
title = "Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?",
abstract = "Study objective: To evaluate the impact of a week-long course of inhaled albuterol compared with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients with stable COPD. Design and interventions: A double-blind, two-period, crossover evaluation, wherein the subjects inhaled albuterol, two puffs four times a day (qid) for 7 days, or ipratropium, two puffs qid for 7 days, in random sequence. Setting: Outpatients of the Pennsylvania State University Hospital, Lebanon VA Medical Center, and local private office practices. Participants: A sample of 15 subjects with stable COPD with FEV1 <55{\%} predicted. Measurements and results: Variables measured at baseline (no inhaled bronchodilator) and/or on day 7 of each arm included FEV1 (liters), 12-min walk test distance (meters), 'rescue' puffs of metaproterenol needed each week, and dyspnea scoring after walking, on the Borg Category Scale (0 to 10=maximal). There was no significant difference in distance walked in 12 min (mean of 751.0±55.5 [±SE]) vs 755.7±61.3 m) or perceived dyspnea (mean 2.7±0.4 vs 3.3±0.4) during albuterol or ipratropium use. Seven patients preferred ipratropium, seven preferred albuterol, and one had no preference. Conclusion: We conclude that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspnea in patients with stable COPD.",
author = "Sandralee Blosser and Maxwell, {S. L.} and Reeves-Hoche, {M. K.} and Localio, {A. R.} and Zwillich, {C. W.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1378/chest.108.3.730",
language = "English (US)",
volume = "108",
pages = "730--735",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD? / Blosser, Sandralee; Maxwell, S. L.; Reeves-Hoche, M. K.; Localio, A. R.; Zwillich, C. W.

In: Chest, Vol. 108, No. 3, 01.01.1995, p. 730-735.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?

AU - Blosser, Sandralee

AU - Maxwell, S. L.

AU - Reeves-Hoche, M. K.

AU - Localio, A. R.

AU - Zwillich, C. W.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Study objective: To evaluate the impact of a week-long course of inhaled albuterol compared with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients with stable COPD. Design and interventions: A double-blind, two-period, crossover evaluation, wherein the subjects inhaled albuterol, two puffs four times a day (qid) for 7 days, or ipratropium, two puffs qid for 7 days, in random sequence. Setting: Outpatients of the Pennsylvania State University Hospital, Lebanon VA Medical Center, and local private office practices. Participants: A sample of 15 subjects with stable COPD with FEV1 <55% predicted. Measurements and results: Variables measured at baseline (no inhaled bronchodilator) and/or on day 7 of each arm included FEV1 (liters), 12-min walk test distance (meters), 'rescue' puffs of metaproterenol needed each week, and dyspnea scoring after walking, on the Borg Category Scale (0 to 10=maximal). There was no significant difference in distance walked in 12 min (mean of 751.0±55.5 [±SE]) vs 755.7±61.3 m) or perceived dyspnea (mean 2.7±0.4 vs 3.3±0.4) during albuterol or ipratropium use. Seven patients preferred ipratropium, seven preferred albuterol, and one had no preference. Conclusion: We conclude that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspnea in patients with stable COPD.

AB - Study objective: To evaluate the impact of a week-long course of inhaled albuterol compared with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients with stable COPD. Design and interventions: A double-blind, two-period, crossover evaluation, wherein the subjects inhaled albuterol, two puffs four times a day (qid) for 7 days, or ipratropium, two puffs qid for 7 days, in random sequence. Setting: Outpatients of the Pennsylvania State University Hospital, Lebanon VA Medical Center, and local private office practices. Participants: A sample of 15 subjects with stable COPD with FEV1 <55% predicted. Measurements and results: Variables measured at baseline (no inhaled bronchodilator) and/or on day 7 of each arm included FEV1 (liters), 12-min walk test distance (meters), 'rescue' puffs of metaproterenol needed each week, and dyspnea scoring after walking, on the Borg Category Scale (0 to 10=maximal). There was no significant difference in distance walked in 12 min (mean of 751.0±55.5 [±SE]) vs 755.7±61.3 m) or perceived dyspnea (mean 2.7±0.4 vs 3.3±0.4) during albuterol or ipratropium use. Seven patients preferred ipratropium, seven preferred albuterol, and one had no preference. Conclusion: We conclude that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspnea in patients with stable COPD.

UR - http://www.scopus.com/inward/record.url?scp=0029147385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029147385&partnerID=8YFLogxK

U2 - 10.1378/chest.108.3.730

DO - 10.1378/chest.108.3.730

M3 - Article

C2 - 7656624

AN - SCOPUS:0029147385

VL - 108

SP - 730

EP - 735

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -